MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 126 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 0.66 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,630,262 | -20.0% | 24,858 | +26.6% | 0.00% | -25.0% |
Q2 2023 | $4,536,147 | +44.7% | 19,637 | +51.8% | 0.00% | +33.3% |
Q1 2023 | $3,134,360 | +49.7% | 12,938 | -27.7% | 0.00% | +50.0% |
Q1 2021 | $2,094,000 | +5.2% | 17,900 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $1,990,000 | -8.4% | 17,900 | -2.2% | 0.00% | 0.0% |
Q3 2020 | $2,173,000 | +8.4% | 18,300 | +3.4% | 0.00% | 0.0% |
Q2 2020 | $2,005,000 | +84.3% | 17,700 | +8.6% | 0.00% | +100.0% |
Q1 2020 | $1,088,000 | -27.6% | 16,300 | -1.2% | 0.00% | 0.0% |
Q4 2019 | $1,503,000 | +24.5% | 16,500 | +17.9% | 0.00% | 0.0% |
Q3 2019 | $1,207,000 | +84.6% | 14,000 | +124.4% | 0.00% | 0.0% |
Q2 2019 | $654,000 | -4.0% | 6,238 | +14.7% | 0.00% | 0.0% |
Q1 2019 | $681,000 | +9.1% | 5,438 | -1.8% | 0.00% | 0.0% |
Q4 2018 | $624,000 | -72.8% | 5,538 | -48.3% | 0.00% | -66.7% |
Q3 2018 | $2,295,000 | +38.9% | 10,718 | +81.4% | 0.00% | +50.0% |
Q2 2018 | $1,652,000 | +265.5% | 5,908 | +52.7% | 0.00% | +100.0% |
Q1 2018 | $452,000 | – | 3,868 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |